Zydus Wellness Sees ₹879 Crore Block Deal; Stock Jumps Nearly 4%

About 46.27 lakh shares of Zydus Wellness, representing over 7% stake in the company, changed hands in the pre-open block deal window

Zydus Wellness
At its intraday high, Zydus Wellness shares were nearly 33% above the 52-week low level and over 20% below the 52-week high level Photo: Zydus Wellness
info_icon

About 46.27 lakh shares of Zydus Wellness changed hands in the pre-open block deal window on Tuesday, June 17. As much as 7% of the stake in the company changed hands today. The large deal took place at a price of ₹1,900 per share, taking the total transaction amount to ₹879 crore. The stock surged as much 3.7% to its intraday high of ₹1,984 on the National Stock Exchange.

At its intraday high, the stock was nearly 33% above its 52-week low level and over 20% below its 52-week high level. Shares of the company have gained over 7% in the last one year, but have gained only marginally in 2025 so far. However, the stock has gained nearly 9% in the last one month.

After releasing its financial results for the latest quarter, the company also announced a stock split and dividend. It announced a stock split in the ratio of 1:5, which means that one equity share of the company will be split into five. This is the first instance of the company announcing a division of its equity shares. It had also announced a final dividend of ₹6 per share.

The Problem Of Rupee

1 June 2026

Get the latest issue of Outlook Business

amazon

Zydus Wellness posted a 15% on year increase in its net profit of ₹172 crore for the fourth quarter of FY25. Revenue for the March quarter increased 17% on year to ₹913 crore. The company’s earnings before interest, tax, depreciation and amortisation (EBITDA) rose 17% on year to ₹190 crore, while its margin expanded to 20.80%.

Earlier this month, another Zydus group entity, Zydus Lifesciences signed a pact to acquire 6% stake in US-based Agenus Inc for around $16mn, marking its entry into the global biologics contract development and manufacturing organisation sector. This will allow the company to access Agenus's biologics manufacturing units in California, US.

Advertisement

Advertisement

Advertisement

Advertisement

×